MedTrace Logo

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

NCT04549025 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-05-22

No results posted yet for this study

Summary

This is a Phase 2, open-label study to evaluate PD-1 inhibitor pimivalimab (JTX-4014) alone and in combination with vopratelimab (JTX-2011), an ICOS agonist, in biomarker-selected adult subjects with metastatic NSCLC who are PD-1/PD-L1 inhibitor naïve and have progressed on a platinum-based chemotherapy regimen.

Conditions

Interventions

DRUG

Pimivalimab

Specified dose on specified days

DRUG

Vopratelimab

Specified dose on specified days

Sponsors & Collaborators

  • Jounce Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Stew Kroll · Jounce Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-19
Primary Completion
2024-04-25
Completion
2024-04-25
FDA Drug
Yes

Countries

  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Georgia
  • Hungary
  • Latvia
  • Moldova
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549025 on ClinicalTrials.gov